TSHA News and Press, Taysha Gene Therapies Inc. From 03/19/26

2026-03-19 18:23:12 ET More on Taysha Gene Therapies Seeking Alpha’s Quant Rating on Taysha Gene Therapies Historical earnings data for Taysha Gene Therapies Financial information for Taysha Gene Therapies Read the full article on Seeking Alpha ...

2026-03-19 10:20:04 ET Image source: The Motley Fool. Thursday, March 19, 2026 at 8:30 a.m. ET Need a quote from a Motley Fool analyst? Email pr@fool.com Continue reading

2026-03-19 08:02:26 ET More on Taysha Gene Therapies Seeking Alpha’s Quant Rating on Taysha Gene Therapies Historical earnings data for Taysha Gene Therapies Financial information for Taysha Gene Therapies Read the full article on Seeking Alpha ...

Dosed multiple Rett syndrome patients in REVEAL pivotal trial of TSHA-102, with enrollment advancing across multiple sites; on track to complete dosing in Q2 2026 Received FDA clearance to initiate ASPIRE trial in three patients aged 2 to <4 years with inclusion of ≥3 months of safe...

Jasper Therapeutics Inc. (JSPR) is expected to report $-0.79 for Q4 2025 MetaVia Inc. (MTVA) is expected to report $-2.06 for Q4 2025 York Space Systems Inc. (YSS) is expected to report $-0.17 for Q4 2025 Intellicheck Inc. (IDN) is expected to report $0.02 for Q4 2025 Scholastic C...

2026-03-18 13:26:06 ET More on Taysha Gene Therapies Seeking Alpha’s Quant Rating on Taysha Gene Therapies Historical earnings data for Taysha Gene Therapies Financial information for Taysha Gene Therapies Read the full article on Seeking Alpha ...

DALLAS, March 12, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today ann...

Sagimet Biosciences Inc. (SGMT) is expected to report $-0.43 for Q4 2025 Serve Robotics Inc. (SERV) is expected to report $-0.49 for Q4 2025 Swiss Water Decaffeinated Coffee Inc (SWSSF) is expected to report $0.02 for Q4 2025 Verrica Pharmaceuticals Inc. (VRCA) is expected to report $...

DALLAS, March 06, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today ann...

Riskified Ltd. Class A (RSKD) is expected to report $0.02 for Q4 2025 SunOpta Inc. (STKL) is expected to report $0.05 for Q4 2025 One Liberty Properties Inc. (OLP) is expected to report $0.41 for Q4 2025 Tourmaline Oil Corp (TRMLF) is expected to report $0.35 for Q4 2025 StubHub H...